Sochiclim
La Sociedad de Climaterio (SOCHICLIM) es una organización de profesionales sin ánimo de lucro, destinada al Estudio del Climaterio. Tiene como misión, la promoción del conocimiento en climaterio y menopausia. Así como crear espacios de discusión e intercambio de material médico de interés.
Información
sochiclim@gmail.com | TelFax +56 2 2333 4610, Casilla 106, Santiago | Av. Hernando de Aguirre 201 Of. 302, Providencia, Santiago de Chile

Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment

Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment
01 Feb 2017

Maraka S, Mwangi R, McCoy RG, Yao X, Sangaralingham LR Singh Ospina NM, O’Keeffe D, De Ycaza A et al.

OBJECTIVE: To estimate the effectiveness and safety of thyroid hormone treatment among pregnant women with subclinical hypothyroidism. DESIGN: Retrospective cohort study. SETTING: Large US administrative database between 1 January 2010 and 31 December 2014.

PARTICIPANTS: 5405 pregnant women with subclinical hypothyroidism, defined as untreated thyroid stimulating hormone (TSH) concentration 2.5-10 mIU/L.

EXPOSURE: Thyroid hormone therapy.

MAIN OUTCOME MEASURE:  Pregnancy loss and other pre-specified maternal and fetal pregnancy related adverse outcomes.

RESULTS: Among 5405 pregnant women with subclinical hypothyroidism, 843 with a mean pre-treatment TSH concentration of 4.8 (SD 1.7) mIU/L were treated with thyroid hormone and 4562 with a mean baseline TSH concentration of 3.3 (SD 0.9) mIU/L were not treated (P<0.01). Pregnancy loss was significantly less common among treated women (n=89; 10.6%) than among untreated women (n=614; 13.5%) (P<0.01). Compared with the untreated group, treated women had lower adjusted odds of pregnancy loss (odds ratio 0.62, 95% confidence interval 0.48 to 0.82) but higher odds of preterm delivery (1.60, 1.14 to 2.24), gestational diabetes (1.37, 1.05 to 1.79), and pre-eclampsia (1.61, 1.10 to 2.37); other pregnancy related adverse outcomes were similar between the two groups. The adjusted odds of pregnancy loss were lower in treated women than in untreated women if their pre-treatment TSH concentration was 4.1-10 mIU/L (odds ratio 0.45, 0.30 to 0.65) but not if it was 2.5-4.0 mIU/L (0.91, 0.65 to 1.23) (P<0.01).

CONCLUSION: Thyroid hormone treatment was associated with decreased risk of pregnancy loss among women with subclinical hypothyroidism, especially those with pre-treatment TSH concentrations of 4.1-10 mIU/L. However, the increased risk of other pregnancy related adverse outcomes calls for additional studies evaluating the safety of thyroid hormone treatment in this patient population.

 

BMJ, 25 de enero de 2017

 

Comentarios

Compartir